163 related articles for article (PubMed ID: 28760447)
1. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? YES.
Wiertlewski S
Rev Neurol (Paris); 2017 Dec; 173(10):610-613. PubMed ID: 28760447
[No Abstract] [Full Text] [Related]
2. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No.
Labauge P
Rev Neurol (Paris); 2017 Dec; 173(10):614-615. PubMed ID: 29102328
[No Abstract] [Full Text] [Related]
3. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care.
Stankoff B
Rev Neurol (Paris); 2017 Dec; 173(10):616-618. PubMed ID: 29128153
[No Abstract] [Full Text] [Related]
4. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
[TBL] [Abstract][Full Text] [Related]
5. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
7. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
[No Abstract] [Full Text] [Related]
8. Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis.
Branco LP; Adoni T; Apostolos-Pereira SL; Brooks JBB; Correa EC; Damasceno CA; Eboni ACB; Fezer L; Gama PDD; Goncalves MVM; Gomes S; Grzesiuk AK; Mendes MF; Morales RR; Muniz A; Parolin MFK; Pimentel MLV; Ribeiro MC; Santos GACD; Sato HK; Scherpenhuijzen SB; Scorcine C; Siquineli F; Sousa NAC; Varela DL; Winckler TCA; Fragoso YD
Arq Neuropsiquiatr; 2018 Sep; 76(9):588-591. PubMed ID: 30365621
[TBL] [Abstract][Full Text] [Related]
9. Anti-JC virus antibody titres increase over time with natalizumab treatment.
Raffel J; Gafson AR; Malik O; Nicholas R
Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
[TBL] [Abstract][Full Text] [Related]
10. Anti-JC virus seroprevalence in a Finnish MS cohort.
Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
[TBL] [Abstract][Full Text] [Related]
11. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
12. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
13. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
14. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
16. PML risk stratification using anti-JCV antibody index and L-selectin.
Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
[TBL] [Abstract][Full Text] [Related]
17. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
18. JCV serology in time: 3 years of follow-up.
Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
O'Connor PW
Can J Neurol Sci; 2012 Sep; 39(5):670-5. PubMed ID: 22931715
[No Abstract] [Full Text] [Related]
20. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
